...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs and aging >Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: A meta-analysis of phase iiia trials
【24h】

Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: A meta-analysis of phase iiia trials

机译：胰岛素脱地格的老年糖尿病患者夜间低血糖发生率比甘精胰岛素低：iiia期临床试验的荟萃分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and Objective Elderly patients with diabetes are more vulnerable to the occurrence and effects of hypoglycaemia; therefore, treatments with low risk of hypoglycaemia are preferred in this population. This study aimed to compare hypoglycaemia rates between insulin degludec (IDeg) and insulin glargine (IGlar) in elderly patients. Methods Hypoglycaemia data from patients ≥65 years of age with type 1 (T1DM) or type 2 (T2DM) diabetes from seven randomised, treat-to-target phase IIIa trials were used to compare IDeg and IGlar in a pre-planned metaanalysis. Overall, 917/4345 (21 %) randomised patients in the seven trials were elderly (634 IDeg, 283 IGlar). Overall confirmed hypoglycaemia was defined as<3.1 mmol/L or severe hypoglycaemia (symptoms requiring external assistance). Nocturnal hypoglycaemia included confirmed episodes from 0001 to 0559 hours (inclusive). Treatment comparisons of hypoglycaemia in T1DM patients were not performed due to low numbers of elderly patients with T1DM randomised (43 IDeg, 18 IGlar); statistical comparisons were also not made for severe hypoglycaemia due to the low number of events. Results In elderly patients with T2DM, the rate of overall confirmed hypoglycaemia was significantly lower with IDeg than IGlar [estimated rate ratio (ERR) 0.76 (0.61; 0.95)95 % CI]; nocturnal confirmed hypoglycaemia was also significantly lower with IDeg [ERR 0.64 (0.43; 0.95)95 % CI]. Confirmed hypoglycaemia occurred in the majority of T1DM patients, whereas severe episodes occurred infrequently and at similar rates in both treatment groups in T1DM and T2DM. Conclusion Results of this pre-planned meta-analysis in elderly patients with diabetes demonstrate a significant reduction in hypoglycaemic events with IDeg relative to IGlar
机译：背景与目的老年糖尿病患者更容易发生低血糖症及其影响。因此，在这一人群中，低血糖风险低的治疗方法是首选。这项研究的目的是比较老年患者的胰岛素德格列酮（IDeg）和甘精胰岛素（IGlar）之间的低血糖发生率。方法采用七项随机，治疗至目标的IIIa期试验，从≥65岁的1型（T1DM）或2型（T2DM）糖尿病患者中获得低血糖数据，以比较IDeg和IGlar在预先计划的荟萃分析中的作用。总体而言，在这7项试验中，有917/4345名患者（21％）是老年患者（634 IDeg，283 IGlar）。总体确诊的低血糖定义为<3.1 mmol / L或严重的低血糖（症状需要外部协助）。夜间低血糖包括从0001到0559小时（含）的确诊发作。 T1DM患者低血糖的治疗比较未完成，原因是老年T1DM患者的随机性较低（43 IDeg，18 IGlar）;由于事件数量少，严重低血糖症也没有进行统计比较。结果在老年T2DM患者中，IDeg的总体确诊低血糖发生率明显低于IGlar [估计比率（ERR）0.76（0.61; 0.95）95％CI];夜间确诊的低血糖症也显着降低了IDeg [ERR 0.64（0.43; 0.95）95％CI]。确诊的低血糖症发生在大多数T1DM患者中，而在T1DM和T2DM的两个治疗组中很少发生严重发作，并且发生率相似。结论这项针对老年糖尿病患者的预先计划荟萃分析的结果表明，与IGlar相比，IDeg的降血糖事件显着减少

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号